UNSPSC 51171842: Denipride

This classification denotes an antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T5IBT2ZQS3. European Medicines Agency schedules Denipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06976MIG. Denipride generally arises in the molecular formula C18H26N4O5.

UNSPSC 51171842 Denipride, a Commodity code, covers drug-testing and specimen-collection services for offender monitoring and criminal-justice populations — a specialized subset of laboratory and clinical testing that state and local criminal-justice agencies procure to support community supervision, probation, and parole compliance programs. Recent solicitations show state and local governments buying staffed collection-site operations, immunoassay screening with chromatographic confirmation (LC/MS/MS or GC/MS), electronic result reporting, alternative matrices (oral fluid and hair testing), and randomized-notification systems via Interactive Voice Response platforms. The issuing bodies are primarily county and state criminal-justice or community-supervision departments; the Texas Health and Human Services Commission and Minnesota Department of Administration also appear in the opportunity set, though the latter two solicitations (a therapeutic pharmacy initiative RFI and a generic pharmaceutical cooperative) show limited direct alignment with the code's core drug-testing scope.

Collin County Community Supervision and Corrections Department in Texas posted the most directly relevant recent opportunity — RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, due July 23, 2026, with an estimated contract value of $600,000 over two years plus three optional one-year renewals. The county seeks vendors to staff two collection sites in Plano and McKinney during standard business hours plus five Saturdays annually, process approximately 25,031 tests annually (five-panel and six-panel screens with confirmation), and maintain SAMHSA, Texas DPS, or CAP lab certification. Vendors must submit per-test pricing across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with cost weighted at 30 percent of the evaluation score alongside vendor understanding (30 points), firm qualifications (25 points), and client references (15 points). The anticipated award date is August 10, 2026. Activity under this code remains concentrated in Texas, with no evidence of widespread multistate procurement for offender drug testing at present.